E83.110 Insurance Policy Changes

ICD-10 E83.110 is officially defined as "Hereditary hemochromatosis." code E83.110 is referenced in 9 tracked payer policy changes from Aetna and Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code E83.110 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 29, 2026Medium impact
Noninvasive Tests for Hepatic Fibrosis (CPB 0690, reviewed 2026-10-26)
This Aetna Clinical Policy Bulletin (CPB 0690) addresses noninvasive tests for hepatic fibrosis and lists which tests Aetna considers medically necessary and which it considers experimental, investigational, or unproven. Aetna considers transient elastography (e.g., FibroScan) medically necessary for follow-up of primary sclerosing cholangitis, monitoring of liver function in Wilson's disease, and distinguishing hepatic cirrhosis from non-cirrhosis in persons with hepatitis B, hepatitis C or other chronic liver diseases. Performing transient elastography, magnetic resonance elastography, the Enhanced Liver Fibrosis (ELF) test, or FibroTest-ActiTest/HCV-FibroSure more than twice per year is considered not medically necessary.
Aetna · Identified Oct 5, 2026Medium impact
Therapeutic Phlebotomy (CPB 0652, reviewed 2026-09-25)
Aetna considers therapeutic phlebotomy medically necessary for erythrocytosis of undetermined etiology with a hematocrit of 55% or higher, hemochromatosis (including hereditary hemochromatosis), individuals receiving testosterone therapy with a hematocrit of 54% or higher (or hemoglobin of 180 g/L or higher), non-alcoholic fatty liver disease with hyperferritinemia, non-hereditary hemochromatosis iron overload with elevated hepatic iron concentration, polycythemia vera, polycythemia secondary to arteriovenous fistulae, cor pulmonale or cyanotic congenital heart disease (for hematocrit greater than 60%), porphyria cutanea tarda, and sickle cell crisis. The policy lists acute gouty arthritis, chronic hepatitis C, chronic urticaria, the common cold, hyperferritinemia in alcohol liver disease, hypertension, migraines, myeloproliferative disorders without polycythemia vera, and progressive multiple sclerosis as experimental, investigational or unproven for phlebotomy treatment. CPT 99195 (phlebotomy, therapeutic, separate procedure) is covered if the selection criteria are met.
Aetna · Identified Oct 4, 2026Medium impact
Genetic Testing (CPB 0140, reviewed 2026-08-18)
Aetna covers genetic testing only when the criteria for the specific condition are met, and it considers testing outside those criteria experimental, investigational, or unproven, including testing for Parkinson disease, essential tremor, coronary artery disease (except testing for familial hypercholesterolemia), and type 2 diabetes other than MODY. Multi-gene panels for inherited cancers are covered only for members with a personal or family history of a related cancer when more than one inherited cancer syndrome could explain the presentation and the panel is more efficient than separate tests, and genetic testing for inherited cancers is a once-in-a-lifetime benefit. Expanded carrier screening for people who are pregnant or planning a pregnancy is covered when the panel includes cystic fibrosis, spinal muscular atrophy, and/or hemoglobinopathies, unless previously performed, and the results will be used in managing the pregnancy or for family planning; whole exome or whole genome sequencing is covered for an unexplained congenital or neurodevelopmental disorder when its listed criteria are met, and whole genome sequencing after a non-diagnostic whole exome test is considered not medically necessary.
Aetna · Identified Aug 18, 2026Medium impact
Therapeutic Phlebotomy (CPB 0652, reviewed 2025-12-08)
Aetna considers therapeutic phlebotomy medically necessary for erythrocytosis of undetermined etiology with hematocrit of 55% or higher, hemochromatosis including hereditary hemochromatosis, testosterone therapy when hematocrit is 54% or higher or hemoglobin is 180 g/L or higher, non-alcoholic fatty liver disease with hyperferritinemia, non-hereditary hemochromatosis iron overload with elevated hepatic iron concentration, polycythemia vera, porphyria cutanea tarda, and sickle cell crisis. Polycythemia secondary to arterio-venous fistulae, cor pulmonale, or cyanotic congenital heart disease is covered for persons with hematocrit greater than 60%. Aetna considers therapeutic phlebotomy experimental, investigational, or unproven for acute gouty arthritis, chronic hepatitis C as adjunctive therapy with interferon, chronic urticaria, the common cold, hyperferritinemia in alcohol liver disease, hypertension, migraines, myeloproliferative disorders without polycythemia vera, and progressive multiple sclerosis.
Aetna · Identified Aug 18, 2026Medium impact
Noninvasive Tests for Hepatic Fibrosis (CPB 0690, reviewed 2026-06-18)
Aetna's Clinical Policy Bulletin 0690 on noninvasive tests for hepatic fibrosis, reviewed 2026-06-18, states which tests it considers medically necessary and which it considers experimental, investigational or unproven. Aetna considers transient elastography (e.g., FibroScan), FibroTest-ActiTest/HCV-FibroSure, magnetic resonance elastography and the Enhanced Liver Fibrosis (ELF) test medically necessary for the indications listed, and considers baseline liver elastography medically necessary for persons with cystic fibrosis who have hepatobiliary involvement. Each of the four tests is considered not medically necessary if performed more than twice per year. Transient elastography and FibroTest-ActiTest/HCV-FibroSure are considered not medically necessary within 6 months of a liver biopsy or of each other, and magnetic resonance elastography and ELF are considered not medically necessary within 6 months of a liver biopsy or another test for liver fibrosis. ARFI, LiverMultiScan, artificial intelligence for NAFLD, NASHnext and the OWLiver Panel are listed as experimental, investigational or unproven for the uses the policy names.
Aetna · Identified Aug 16, 2026Medium impact
Intravenous Iron Therapy (CPB 0575, reviewed 2026-07-01)
Feraheme, Ferrlecit, Injectafer, Monoferric and Venofer are medically necessary only for commercial members who have a contraindication, intolerance or ineffective response to the lower cost alternatives generic ferumoxytol, generic iron sucrose, generic sodium ferric gluconate and INFeD (iron dextran) for the labeled indication. Precertification is required for Feraheme, Ferrlecit, generic sodium ferric gluconate, Injectafer, Monoferric, Venofer and generic iron sucrose in applicable plan designs. Intravenous iron is considered experimental, investigational or unproven for other indications, including acute mountain sickness and anemia of inflammation, and it is contraindicated for genetic hemochromatosis or hemochromatosis secondary to iron overload.
Aetna · Identified Aug 13, 2026Medium impact
Plasmapheresis/Plasma Exchange/Therapeutic Apheresis (CPB 0285, reviewed 2026-04-16)
Aetna considers plasmapheresis, plasma exchange and therapeutic apheresis medically necessary for a list of indications. These include acute humoral rejection of renal transplants, acute severe neurological deficits from multiple sclerosis that respond poorly to high-dose glucocorticoids, severe (grades 3 to 5) Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP) with severe or life-threatening symptoms, thrombotic thrombocytopenic purpura, and sickle cell disease. Plasmapheresis, plasma exchange or therapeutic apheresis for all other indications, including Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, sepsis or septic shock, and ulcerative colitis, is considered experimental, investigational, or unproven.
Aetna · Identified Aug 12, 2026Medium impact
Chelation Therapy (CPB 0234, reviewed 2026-02-11)
Deferoxamine mesylate is considered medically necessary for transfusional iron overload in members with chronic anemia when the pretreatment serum ferritin is greater than 1000 mcg/L, for aluminum toxicity in members undergoing dialysis, and for hereditary hemochromatosis when phlebotomy is not an option or the member had an unsatisfactory response to phlebotomy, and it must be prescribed by or in consultation with a hematologist or nephrologist. Other chelation therapy is considered medically necessary for conditions including aceruloplasminemia, biliary cirrhosis, Cooley's anemia, cystinuria, Diamond-Blackfan anemia, sickle cell anemia, Wilson's disease, secondary hemochromatosis, and heavy metal toxicity when symptoms are suggestive and toxicity is confirmed by laboratory testing. Chelation therapy for cancer, cardiovascular disease, neurodegenerative diseases, autism, ADHD, and mercury toxicity from dental amalgam fillings is considered experimental, investigational, or unproven.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Low impact
Phlebotomy, Therapeutic
This is a policy review for therapeutic phlebotomy coverage under BCBS Mississippi. The policy confirms coverage for specific blood disorders including polycythemia vera, hemochromatosis, and related conditions. No changes were made to coverage criteria or billing codes.

Watch E83.110

Get one email when a payer policy names E83.110, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code E83.110?

There are 9 tracked policy changes affecting code E83.110, including updates from Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code E83.110?

Payers that have issued tracked updates for code E83.110 include: Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code E83.110 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code E83.110. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code E83.110?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Noninvasive Tests for Hepatic Fibrosis (CPB 0690, reviewed 2026-10-26)

Therapeutic Phlebotomy (CPB 0652, reviewed 2026-09-25)

Genetic Testing (CPB 0140, reviewed 2026-08-18)

Therapeutic Phlebotomy (CPB 0652, reviewed 2025-12-08)

Noninvasive Tests for Hepatic Fibrosis (CPB 0690, reviewed 2026-06-18)

Intravenous Iron Therapy (CPB 0575, reviewed 2026-07-01)

Plasmapheresis/Plasma Exchange/Therapeutic Apheresis (CPB 0285, reviewed 2026-04-16)

Chelation Therapy (CPB 0234, reviewed 2026-02-11)

Phlebotomy, Therapeutic

What insurance policy changes affect code E83.110?

Which payers have updated policy for code E83.110?

How do I get notified when code E83.110 policy changes?

Why do payers change policies for code E83.110?